Hints and tips:
...Myers Squibb Q1, Capital One Q1, Caterpillar Q1, Comcast Q1, Dassault Systemes Q1, Delivery Hero Q1 trading update, Deutsche Bank Q1, Dow Q1, Drax Group AGM and trading update, Inchcape Q1, Intel Q1, London...
...Myers Squibb to acquire Mirati in up to $5.8bn deal (Reuters) German auto group Schaeffler swoops for Vitesco with €3bn bid (FT) Big banks sit out LBO rebound after being stung by earlier buyouts (FT)...
...US, Federal Open Market Committee makes interest rate announcement with officials signalling a 75 basis point rise Results: Airbus H1, BASF Q2, Boeing Q2, Breedon H1, Bristol Myers Squibb Q2, British...
...All assets may perform badly under stagflation, but we’d rather own Pepsi, Johnson & Johnson, Kimberly-Clark, Bristol-Myers et al than sit and watch our cash lose its earnings power....
...Pharmaceutical company earnings Drugmaker Bristol-Myers Squibb is scheduled to report fourth-quarter results and is expected to post a higher profit than last year on increased sales of its cancer drugs...
...The chief executive of Bristol-Myers Squibb described the US government’s support for waiver as “very concerning” during an interview at the FT US Pharma and Biotech Summit on Thursday....
...From the pharmaceuticals sector, Bristol-Myers Squibb — which recently agreed to buy Celgene in one of the largest pharmaceutical deals in history — reports....
...According to SEC filings, Elon Musk’s company is the $60bn hedge fund’s second largest holding, behind Bristol-Myers Squibb....
...The sale allows Bristol-Myers Squibb to push ahead with its mammoth $90bn takeover of Celgene....
...The two banks have landed on some of the biggest deals of the year, with JPMorgan advising on the $90bn tie-up between Bristol-Myers Squibb and Celgene and Goldman providing advice to Allergan on its $85bn...
...Bristol-Myers Squibb, a mammoth US drugmaker on the brink of completing a $90bn merger with Celgene — one of the largest in pharma history — is Starboard’s latest target....
...Tech-set comes to work crowd ahead of big IPOs It has been an active start to the year for dealmakers, with a number of transactions already announced, including Bristol-Myers Squibb’s $90bn deal for rival...
...The Supreme Court in June ruled in Bristol-Myers Squibb v Superior Court that, in product liability and mass tort cases, plaintiffs can only sue companies in states where they purchase or use the product...
...Prior to joining Unilever, Jean-Marc held the Executive Vice President and Chief Financial Officer roles at Bristol-Myers Squibb Company, as well as a place on the Executive Committee....
...counterbid for ImClone last year in response to an offer from Bristol-Myers Squibb....
...Bristol Myers Squibb was a rare gainer, its shares lifting 1.7 per cent to $21.02 after the US Food and Drug Administration said analyses of its experimental diabetes drug showed it met the agency’s guidelines...
...Atlas can boast a string of successful recent exits, including the $435m sale of Adnexus, the biotechnology company, to Bristol Myers Squibb in 2007....
International Edition